公开(公告)号：EP4353250A3

公开(公告)日：2024-06-19

申请号：EP24158632.0

申请日：2018-06-20

申请人： Amgen Inc.

发明人： WALKER, Kenneth W. ,  HOLDER, Jerry Ryan ,  LLOYD, David J. ,  LU, Shu-Chen ,  VENIANT-ELLISON, Murielle M. ,  STANISLAUS, Shanaka

IPC分类号： C07K16/28 ,  A61K38/26 ,  A61P3/10

CPC分类号： A61K38/26 ,  C07K16/2869 ,  A61P3/10 ,  C07K2317/7620130101 ,  C07K2317/9020130101 ,  C07K2319/7520130101

摘要： Methods of treating metabolic diseases and disorders using a composition comprising a GLP-1/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between.

公开(公告)号：EP3355908A1

公开(公告)日：2018-08-08

申请号：EP16782352.5

申请日：2016-09-30

申请人： Amgen Inc.

发明人： XU, Jing ,  STANISLAUS, Shanaka ,  CHEN, Mei-Hsiu M. ,  HALE, Clarence H. ,  VENIANT-ELLISON, Murielle

IPC分类号： A61K38/18 ,  A61P1/16

CPC分类号： A61K38/1825 ,  A61P1/00 ,  A61P1/16

摘要： The invention relates method of treating a patient in need thereof with a long acting agonist to the FGF21 signaling pathway. In a particular embodiment, the invention relates to the use of molecules that stimulate the FGF21 signaling pathway, such as long acting FGF21 polypeptides or agonist antibodies, to treat disorders or diseases associated with excess bile acid. The invention further relates to pharmaceutical formulations and dosing of long acting agonists of the FGF21 signaling pathway suitable for treating bile acid related disorders.

公开(公告)号：EP4353250A2

公开(公告)日：2024-04-17

申请号：EP24158632.0

申请日：2018-06-20

申请人： Amgen Inc.

发明人： WALKER, Kenneth W. ,  HOLDER, Jerry Ryan ,  LLOYD, David J. ,  LU, Shu-Chen ,  VENIANT-ELLISON, Murielle M. ,  STANISLAUS, Shanaka

IPC分类号： A61K38/26

CPC分类号： A61K38/26 ,  C07K16/2869

摘要： Methods of treating metabolic diseases and disorders using a composition comprising a GLP-1/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between.

公开(公告)号：EP3570885A1

公开(公告)日：2019-11-27

申请号：EP18714635.2

申请日：2018-01-16

申请人： Amgen Inc.

发明人： CHENG, Yuan ,  NETIROJJANAKUL, Chawita ,  HOLDER, Jerry Ryan ,  WU, Bin ,  FALSEY, James R. ,  HERBERICH, Bradley J. ,  SHAM, Kelvin ,  MIRANDA, Leslie P. ,  LU, Shu-Chen ,  VENIANT-ELLISON, Murielle M. ,  STANISLAUS, Shanaka ,  YIE, Junming ,  XU, Jing

IPC分类号： A61K39/395 ,  C07K16/28 ,  A61P3/10

公开(公告)号：EP2750695A2

公开(公告)日：2014-07-09

申请号：EP12766746.7

申请日：2012-08-30

申请人： Amgen Inc.

发明人： ELLISON, Murielle Marie ,  STANISLAUS, Shanaka ,  XU, Jing

IPC分类号： A61K38/18 ,  A61P3/00 ,  A61P3/04 ,  A61P3/06 ,  A61P3/08 ,  A61P3/10

CPC分类号： A61K38/1825

摘要： Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease